NCT06605222 A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
| NCT ID | NCT06605222 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| Condition | Advanced Solid Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 201 participants |
| Start Date | 2024-10-04 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 201 participants in total. It began in 2024-10-04 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-7787 injection monotherapy for patients with advanced solid tumors. To explore the reasonable dosage of SHR-7787 injection monotherapy for patients with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria: 1. Ability to understand and voluntarily agrees to participate by giving written informed consent for the study; 2. Patients with unresectable recurrent or metastatic solid tumors; 3. There is at least one lesion could be measured; 4. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; 5. Adequate organ functions as defined; 6. Life expectancy ≥3 months. Exclusion Criteria: 1. Patients with known active central nervous system (CNS) metastases; 2. Subjects who had other malignancy in five years before the first dose; 3. Patients with tumor-related pain that cannot be controlled as determined; 4. Patients with serious cardiovascular and cerebrovascular diseases; 5. Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion; 6. Patients with Severe infections; 7. History of immunodeficiency; 8. History of autoimmune diseases; 9. Unresolved CTCAE Grade \>1 toxicity attributed to any prior anti-tumor therapy 10. Active infection; 11. Pregnant or nursing women; 12. Known history of serious allergic reactions to the investigational product or its main ingredients.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06605222 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Advanced Solid Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06605222 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06605222 currently recruiting?
Yes, NCT06605222 is actively recruiting participants. Contact the research team at ke.ma@hengrui.com for enrollment information.
Where is the NCT06605222 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06605222 clinical trial?
NCT06605222 is sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. The trial plans to enroll 201 participants.